High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset
Open Access
- 9 February 2010
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 107 (9), 4323-4328
- https://doi.org/10.1073/pnas.0910684107
Abstract
Analysis of chromosomal aberrations is used to determine the prognosis of neuroblastomas (NBs) and to aid treatment decisions. MYCN amplification (MNA) alone is an incomplete poor prognostic factor, and chromosome 11q status has recently been included in risk classification. We analyzed 165 NB tumors using high-density SNP microarrays and specifically compared the high-risk groups defined by MNA (n = 37) and 11q-deletion (n = 21). Median patient age at diagnosis was 21 months for MNA tumors and 42 months for 11q-deletion tumors, and median survival time after diagnosis was 16 months for MNA and 40 months for 11q deletion. Overall survival (at 8 years) was ∼35% in both groups. MNA and 11q deletion were almost mutually exclusive; only one case harbored both aberrations. The numbers of segmental aberrations differed significantly; the MNA group had a median of four aberrations, whereas the 11q-deletion group had 12. The high frequency of chromosomal breaks in the 11q-deletion group is suggestive of a chromosomal instability phenotype gene located in 11q; one such gene, H2AFX, is located in 11q23.3 (within the 11q-deletion region). Furthermore, in the groups with segmental aberrations without MNA or 11q deletion, the tumors with 17q gain have worse prognosis than those with segmental aberrations without 17q gain, which have a favorable outcome. This study has implications for therapy in different risk groups and stresses that genome-wide microarray analyses should be included in clinical management to fully evaluate risk, aid diagnosis, and guide treatment.Keywords
This publication has 29 references indexed in Scilit:
- The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force ReportJournal of Clinical Oncology, 2009
- The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force ReportJournal of Clinical Oncology, 2009
- High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: Four cases of homozygous deletions of the CDKN2A geneBMC Genomics, 2008
- Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumoursBritish Journal of Cancer, 2007
- Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signatureOncogene, 2007
- Highly Sensitive Method for Genomewide Detection of Allelic Composition in Nonpaired, Primary Tumor Specimens by Use of Affymetrix Single-Nucleotide–Polymorphism Genotyping MicroarraysAmerican Journal of Human Genetics, 2007
- Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplificationBritish Journal of Cancer, 2007
- Favorable outcome of triploid neuroblastomas: a contribution to the special oncogenesis of neuroblastomaCancer Genetics and Cytogenetics, 2006
- H2AX Haploinsufficiency Modifies Genomic Stability and Tumor SusceptibilityCell, 2003
- Allelic deletion at 11q23 is common in MYCN single copy neuroblastomasOncogene, 1999